The role of targeted therapy in non-small cell lung cancer
- 1 July 2004
- journal article
- review article
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 51 (1) , 29-44
- https://doi.org/10.1016/j.critrevonc.2004.02.002
Abstract
No abstract availableKeywords
This publication has 64 references indexed in Scilit:
- O-109 Improved quality of life with the addition of SRL172 (killed mycobacterium vaccae) to standard chemotherapy in patients with advanced non-small cell lung cancer: Phase III resultsLung Cancer, 2003
- Celecoxib, a Selective Cyclo-Oxygenase-2 Inhibitor, Enhances the Response to Preoperative Paclitaxel and Carboplatin in Early-Stage Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2003
- Cancer Statistics, 2003CA: A Cancer Journal for Clinicians, 2003
- Antisense therapy for cancer—the time of truthThe Lancet Oncology, 2002
- Novel Targets for Lung Cancer Therapy: Part IIJournal of Clinical Oncology, 2002
- Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growthAnnals of Oncology, 2002
- Anticancer drug targets: approaching angiogenesisJournal of Clinical Investigation, 1999
- Frequency of MAGE-3 gene expression in HLA-A2 positive patients with non-small cell lung cancerLung Cancer, 1998
- Vascular endothelial growth factorTrends in Cardiovascular Medicine, 1993
- What Is the Evidence That Tumors Are Angiogenesis Dependent?JNCI Journal of the National Cancer Institute, 1990